Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.
News|Videos|June 8, 2018
Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC
Author(s)Apar Kishor Ganti, MD, MS
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Advertisement
In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.
Advertisement
Related to this article
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.
The final 3-year OS rate was 72.7% with OST-HER2 vs 45.8% in a combined historical control in a phase 2b trial of pulmonary metastatic osteosarcoma.
Melody Rasouli, MD, MBA, FACOG, discussed the system breakdowns that delay fertility referrals and how EHR triggers can automate the process.
Zachary L. Bercu, MD, RPVI, FSIR, discusses the Liberty robotic system’s applications in liver and kidney cancer as well as the feasibility of remote procedures.
Jan Kitajewski, PhD, discussed how pooled expertise, pilot funding, and investigator support help move bench discoveries toward multicenter trials.
Melody Rasouli, MD, MBA, FACOG, explained why male fertility preservation information trails female content online and how cancer centers can fix it.
Zachary L. Bercu, MD, RPVI, FSIR, explains how the Liberty endovascular robotic system works from the operator’s perspective and what went into becoming its first adopting site.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
4
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
5